Rocket Doctor AI Inc.
AI-Driven Solutions for Next-Generation Virtual Care – Initiating Coverage
Published: Jan 9, 2026
Author: FRC Analysts
Disclosure: Rocket Doctor AI Inc. has paid FRC a fee for research coverage and distribution of reports. See last page for other important disclosures, rating, and risk definitions.
Company Details
Sector – Research Report
Trading Information
Ticker & Exchange – AIDR.CN : CSE
Report Highlights
- Rocket Doctor operates an AI-powered digital health platform and marketplace connecting physicians and patients virtually. With virtual health appointments rising from 1% of visits in early 2020, to over 20% today, it is estimated that the global virtual care market will grow from US$20B in 2025, to US$248B by 2034, at a CAGR of 32% (Precedence Research).
- RD’s platform in Canada, active since 2020, serves ~300 physicians, and handles ~150k appointments annually (700k+ since inception). The company recently expanded to the U.S., potentially reaching ~13M insured members (patients) through partnerships with 10+ insurers. Revenue primarily comes from doctor subscriptions and per-appointment fees, with gross margins of 85–90%. The platform is designed to support millions of appointments annually, backed by thousands of doctors.
- RD’s AI-powered Global Library of Medicine (GLM) is its core IP, offering real-time diagnostic support for 1,000+ diseases and 17,000+ symptoms. Built on 25,000+ hours of clinician input and verified medical content, RD offers solutions for doctors and healthcare providers for diagnosis, treatment planning, patient care, training, and simulation.
- The virtual healthcare space is highly competitive, with both large and small players. We believe RD stands out by offering a model that supports independent physicians, including a digital practice storefront, full operational support, transparent billing, no long-term contracts, and real-time AI assistance; features many competitors lack, as they often provide only partial support and require physician employment.
- While RD’s model is strategically attractive to doctors, we believe patient adoption will depend on marketing effectiveness, platform usability, AI performance, and network size.
- AIDR is trading at 8x forward EBITDA vs the sector average of 22x, a 64% discount. We believe the company’s marketing campaigns in the U.S. over the next year will be decisive in determining whether it can successfully expand in the U.S. virtual care market, providing investors with early exposure to its potential for success.
- Competition from established telehealth providers
- Early-stage operations; not yet profitable
- New entrant in the U.S.
- Cybersecurity and data privacy risks
- Scaling challenges in building doctor and patient networks
Price and Volume (1-year)

| YTD | 12M | |
| KIDZ | 50% | 25% |
| TSXV | 13% | 15% |
Building an AI-powered healthcare marketplace A two-pronged business model targeting patients (B2C) and healthcare institutions (B2B)B2C: Physician-Funded Model (Primary
Company Overview Evolution Timeline
The opinions expressed in this report are the true opinions of the analyst(s) about any companies and industries mentioned. Any “forward looking statements” are our best estimates and opinions based upon information that is publicly available and that we believe to be correct, but we have not independently verified with respect to truth or correctness. There is no guarantee that our forecasts will materialize. Actual results will likely vary. The companies listed above are covered by FRC under an issuer-paid model, where fees have been paid to FRC to commission this report and research coverage. This creates a potential conflict of interest which readers should consider. Distribution procedure: our reports are distributed first to our web-based subscribers on the date shown on this report then made available to delayed access users through various other channels for a limited time. To subscribe for real-time access to research, visit https://www.researchfrc.com/plans for subscription options. This report contains “forward looking” statements. Forward-looking statements regarding the Company, industry, and/or stock’s performance inherently involve risks and uncertainties that could cause actual results to differ from such forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products/services in the marketplace; acceptance in the marketplace of the Company’s new product lines/services; competitive factors; new product/service introductions by others; technological changes; dependence on suppliers; systematic market risks and other risks discussed in the Company’s periodic report filings, including interim reports, annual reports, and annual information forms filed with the various securities regulators. By making these forward-looking statements, Fundamental Research Corp. and the analyst/author of this report undertakes no obligation to update these statements for revisions or changes after the date of this report. Fundamental Research Corp DOES NOT MAKE ANY WARRANTIES, EXPRESSED OR IMPLIED, AS TO RESULTS TO BE OBTAINED FROM USING THIS INFORMATION AND MAKES NO EXPRESS OR IMPLIED WARRANTIES OR FITNESS FOR A PARTICULAR USE. ANYONE USING THIS REPORT ASSUMES FULL RESPONSIBILITY FOR WHATEVER RESULTS THEY OBTAIN FROM WHATEVER USE THE INFORMATION WAS PUT TO. ALWAYS TALK TO YOUR FINANCIAL ADVISOR BEFORE YOU INVEST. WHETHER A STOCK SHOULD BE INCLUDED IN A PORTFOLIO DEPENDS ON ONE’S RISK TOLERANCE, OBJECTIVES, SITUATION, RETURN ON OTHER ASSETS, ETC. ONLY YOUR INVESTMENT ADVISOR WHO KNOWS YOUR UNIQUE CIRCUMSTANCES CAN MAKE A PROPER RECOMMENDATION AS TO THE MERIT OF ANY PARTICULAR SECURITY FOR INCLUSION IN YOUR PORTFOLIO. This REPORT is solely for informative purposes and is not a solicitation or an offer to buy or sell any security. It is not intended as being a complete description of the company, industry, securities or developments referred to in the material. Any forecasts contained in this report were independently prepared unless otherwise stated, and HAVE NOT BEEN endorsed by the Management of the company which is the subject of this report. Additional information is available upon request. THIS REPORT IS COPYRIGHT. YOU MAY NOT REDISTRIBUTE THIS REPORT WITHOUT OUR PERMISSION. Please give proper credit, including citing Fundamental Research Corp and/or the analyst, when quoting information from this report. The information contained in this report is intended to be viewed only in jurisdictions where it may be legally viewed and is not intended for use by any person or entity in any jurisdiction where such use would be contrary to local regulations or which would require any registration requirement within such jurisdiction.
